分子靶向药物及其联合经动脉化疗栓塞术在肝细胞癌治疗中的研究进展  

Research progress of combined molecular targeted therapy with transarterial chemoembolization on hepatocellular carcinoma

作　　者：王蕊 王洋[2] 李威[2] WANG Rui;WANG Yang;LI Wei(Infection Center, Beijing You＇an Hospital, Beijing 100069, China)

机构地区：[1]首都医科大学附属北京佑安医院艾滋病实验室,北京100069 [2]首都医科大学附属北京佑安医院肿瘤微创介入中心,北京100069

出　　处：《中国病毒病杂志》2017年第6期453-458,共6页Chinese Journal of Viral Diseases

基　　金：国家重大科研装备研制项目(ZDYZ2015-2);北京市卫生系统高层次卫生技术人才培养计划:北京市百千万人才工程(2014-3-088)

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是全球最难治疗的恶性肿瘤之一,每年的发病率超过74.8万人,早期肝细胞癌可通过手术切除、原位肝移植或局部消融达到治愈,但是患者往往发现时已是肝细胞癌晚期,因此不适宜用外科切除或介入手段。分子靶向药具有特异性高、不良反应轻微等特点,目前在恶性肿瘤个体化治疗中扮演重要角色。索拉菲尼作为首个可用于临床治疗晚期HCC的分子靶向药物,近年来所获得临床效果不可忽视。本文就分子靶向药物在肝细胞癌治疗中的最新应用进展以及联合经动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)在肝癌中的治疗作一综述。Hepatocellular carcinoma （HCC） is one of the most difficult malignant tumors to treat. Newly diagnosed patients is more than 748 thousands every year. Surgery, liver transplantation or local ablation can be applied to treat early stage of HCC but not suitable for late stage patients. Molecular targeted drugs are characterized with high specificity and slight side effects and thus plays an important role in the individualized treatment of malignant tumors. As the first molecular targeted drug for the treatment of late stage HCC, sorafenib demonstrated satisfied clinical effects in recent years. In this review, we summarize the research progresses in clinical application of combined molecular targeted drugs with transarterial chemoembolization （TACE） in the treatment of HCC.

关 键 词：肝细胞癌 进展期 分子靶向药物 治疗 

分 类 号：R735.7[医药卫生—肿瘤]